Breaking News
LAST CHANCE for Cyber Monday SALE: Up to 54% off InvestingPro! Register here
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Ionis Pharmaceuticals Inc (IONS)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Ionis Pharma's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
27.45 -1.60    -5.51%
15:59:59 - Closed. Currency in USD ( Disclaimer )
After Hours
27.50
+0.05
+0.18%
17:53:48 - Real-time Data
Type:  Equity
Market:  United States
ISIN:  US4622221004 
CUSIP:  462222100
  • Volume: 1,610,825
  • Bid/Ask: 27.50 / 27.85
  • Day's Range: 27.39 - 29.48
Ionis Pharma 27.45 -1.60 -5.51%

IONS Cash Flow Statement

 
Featured here, the Cash Flow Statement for Ionis Pharmaceuticals Inc, showing the changes in the company's cash and cash equivalents, broken down to operating, investing and financing activities over each of the last 4 periods (either quarterly or annually).
AnnualQuarterly
Collapse All
Period Ending: 2021
30/09
 2021
30/06
 2021
31/03
 2020
31/12
Period Length: 0 Months 6 Months 3 Months 12 Months
Net Income/Starting Line -253.21 -170.74 -89.87 -486.77
Cash From Operating Activities -172.89 -117.31 -54.66 35.89
Depreciation/Depletion 11.66 7.95 3.92 13.37
Amortization 1.74 1.14 0.54 2.06
Deferred Taxes - - - 313.27
Non-Cash Items 125.53 88.26 43.35 267.51
Cash Receipts - - - -
Cash Payments - - - -
Cash Taxes Paid - - - 25.86
Cash Interest Paid 3.53 2.87 0.59 6.25
Changes in Working Capital -58.62 -43.92 -12.6 -73.56
Cash From Investing Activities 99.8 -22.17 78.86 274.48
Capital Expenditures -9.45 -6.13 -1.77 -35.12
Other Investing Cash Flow Items, Total 109.25 -16.04 80.63 309.6
Cash From Financing Activities 308.42 306.96 -7.58 -596.61
Financing Cash Flow Items -168.43 -167.97 -15.34 -544.69
Total Cash Dividends Paid - - - -
Issuance (Retirement) of Stock, Net 101.32 99.39 7.76 -51.92
Issuance (Retirement) of Debt, Net 375.54 375.54 - -
Foreign Exchange Effects -0.04 -0.02 -0.13 0.62
Net Change in Cash 235.29 167.46 16.49 -285.62
Beginning Cash Balance - - - -
Ending Cash Balance - - - -
Free Cash Flow - - - -
Free Cash Flow Growth - - - -
Free Cash Flow Yield - - - -
* In Millions of USD (except for per share items)
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

IONS Comments

Write your thoughts about Ionis Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Tullio Bressanello
Tullio Bressanello Oct 01, 2021 10:39AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
What’s about this stock? Any new therapies are coming out?
Reply
0 0
Report
Crim Jamer
Crim Jamer Oct 01, 2021 10:39AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I think shareholders needs a therapy now. BIIB / IONIS Tofersen (BIIB067) Phase 3 test did unsuccesful
Reply
0 0
Report
Bobo Müller
Bobo Müller Jun 09, 2021 12:11PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Absolutely underrated stock. See you in ten years or this fall when the product in cooperation with Biogen comes out
Reply
0 0
Report
Kurt Maxberry
Kurt Maxberry Jun 07, 2021 11:59AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Added 4000 at 34.4
Reply
0 1
Report
Crim Jamer
Crim Jamer May 20, 2021 4:32PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
nice after market move!
Reply
0 0
Report
Luke Sky
Luke Sky Apr 24, 2021 1:22PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Give the anti-corona spray from marinomed-biotech some VC and invest in a pharma company which is heading to the moon:https://www.investing.com/equities/marinomed-biotech-agStudies are proving that the patented method of marinomed prevents infection with all Corona varietis including mutants. It also prevents other virus infections. They have many patents.  Do some good and get rich
Reply
1 0
Report
Crim Jamer
Crim Jamer Mar 22, 2021 5:13PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
CARLSBAD, Calif., March 22, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced its partner, Roche, has decided to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington's disease (HD). The decision was based on the results of a pre-planned review of data from the Phase III study conducted by an unblinded Independent Data Monitoring Committee (iDMC). While there were no new or emerging safety signals identified for tominersen, the iDMC made its recommendation based on the investigational therapy's potential benefit/risk profile for study participants. Participants will continue to be followed for safety and clinical outcomes.
Reply
0 0
Report
Sean Landolt
Sean Landolt Sep 30, 2020 3:15PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
this stock doesn't know what a green day looks like.
Reply
3 0
Report
형진 조
형진 조 Sep 14, 2019 1:49PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
ㅜㅜ~
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email